Source: American journal of nephrology. Unidade: FM
Subjects: HEMOGLOBINAS, DOENÇAS CARDIOVASCULARES, INSUFICIÊNCIA RENAL CRÔNICA, DIABETES MELLITUS, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
ABNT
CAUSLAND, Finnian R. Mc et al. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American journal of nephrology, v. 46, n. 6, p. 488-497, 2017Tradução . . Disponível em: https://doi.org/10.1159/000485326. Acesso em: 15 out. 2024.APA
Causland, F. R. M., Claggett, B., Pfeffer, M. A., Burdmann, E. de A., Eckardt, K. -U., Levey, A. S., et al. (2017). Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American journal of nephrology, 46( 6), 488-497. doi:10.1159/000485326NLM
Causland FRM, Claggett B, Pfeffer MA, Burdmann E de A, Eckardt K-U, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial [Internet]. American journal of nephrology. 2017 ; 46( 6): 488-497.[citado 2024 out. 15 ] Available from: https://doi.org/10.1159/000485326Vancouver
Causland FRM, Claggett B, Pfeffer MA, Burdmann E de A, Eckardt K-U, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial [Internet]. American journal of nephrology. 2017 ; 46( 6): 488-497.[citado 2024 out. 15 ] Available from: https://doi.org/10.1159/000485326